Gastrointestinal Cancer

Registry Data Suggest TaTME Is Safe and Effective for Rectal Cancer

By

Andrea S. Blevins Primeau, PhD, MBA

Publish Date September 16, 2021

The 2-year actuarial rate of local recurrence was 4.8%.

Tislelizumab Under Review for Esophageal Squamous Cell Carcinoma

By

Brian Park, PharmD

Publish Date September 13, 2021

The application is supported by data from the phase 3 RATIONALE 302 trial.

Infigratinib Shows Potential for Treating Advanced Cholangiocarcinoma with FGFR2 Alterations

By

Sucharita Mistry, PhD

Publish Date August 27, 2021

The objective response rate was 23.1%, and the disease control rate was 84.3%.

Risk of Gastrointestinal Cancer Linked to Frequency of Alcohol Consumption

By

Leah Lawrence

Publish Date August 27, 2021

Frequency of alcohol consumption may be more important than the amount of alcohol consumed.

Study Compares Prevalence, Severity of Peripheral Neuropathy in CRC Survivors and Patients With Diabetes

By

Jennifer Larson

Publish Date August 25, 2021

A comparison of data from 2 studies on peripheral neuropathy found that CRC survivors would benefit from education related to recognizing early symptoms.